Trial Profile

Neoadjuvant Treatment of Nimotuzumab With Chemotherapy or Radiotherapy Versus Surgery Alone in Resectable Esophageal Squamous Cell Carcinoma

Status: Withdrawn prior to enrolment

Phase of Trial: Phase II/III

Latest Information Update: 05 Aug 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Cisplatin (Primary) ; Nimotuzumab (Primary) ; Paclitaxel (Primary)
Indications Oesophageal cancer; Squamous cell cancer
Focus Therapeutic Use

Most Recent Events

16 Mar 2021 Status changed from suspended to withdrawn prior to enrolment.
16 Mar 2021 Planned End Date changed from 1 Dec 2018 to 1 Dec 2020.
16 Mar 2021 Planned primary completion date changed from 1 Dec 2018 to 1 Dec 2020.

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com